mesothelioma

Researchers identified unique ALK rearrangements in patients that lack previously known indicators of mesothelioma.

This Week in PNAS

In PNAS this week: recurrent deletions in mesothelioma patients, mutagenesis screen for genes working with PTEN in triple-negative breast cancer, and more.

This Week in Nature

In Nature this week: genome-wide association study links genetic variants to a number of hair traits, and more.

Genomic and transcriptomic sequence data from hundreds of mesothelioma tumors has uncovered recurrent gene mutations, gene fusions, and pathway alterations.

Survey results reflect strong penetration of Castle Biosciences' uveal melanoma test among specialists as the company plans a future focus on more prevalent diseases.

NEW YORK (GenomeWeb) – Australia's Asbestos Diseases Research Institute (ADRI) has recently begun enrolling patients in a Phase I trial of a microRNA-based treatment for malignant pleural mesothelioma (MPM), marking the second time a drug based on the small, non-coding RNAs has moved into human t

NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Castle Biosciences today said that it raised $11.8 million in a Series E financing round.

Proteomics diagnostics firm Somalogic reported data this week supporting the utility of its blood-based 13-protein panel for the detection of malignant mesothelioma.

NEW YORK (GenomeWeb News) – Castle Biosciences has licensed the IP and technology rights from Brigham and Women's Hospital for a gene expression profiling test for mesothelioma, the company announced today.

Blood levels of the microRNA miR-625-3p could serve as a predictive biomarker for the early diagnosis of malignant pleural mesothelioma, according to research by a group from the Concord Hospital Asbestos Diseases Research Institute in Sydney, Australia.

Pages

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.